STOCK TITAN
  1. Home
  2. News
  3. ERNA

Eterna Therapeutics Inc. - $ERNA STOCK NEWS

Welcome to our dedicated page for Eterna Therapeutics news (Ticker: $ERNA), a resource for investors and traders seeking the latest updates and insights on Eterna Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eterna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eterna Therapeutics's position in the market.

News
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Rhea-AI Summary

Eterna Therapeutics Inc. (Nasdaq: ERNA) appoints Dr. Mahendra Rao, an expert in regenerative medicine and cell engineering, to its Scientific Advisory Board. Dr. Rao brings extensive experience in clinical trials and stem cell research to support Eterna's mRNA cell engineering initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
Rhea-AI Summary

Eterna Therapeutics Inc. (ERNA) is set to present at the ASGCT 27th Annual Meeting on the development of a mRNA-engineered iPSC line mimicking native B2M expression by inserting HLA-E at the B2M locus. The technology aims to enhance safety and efficacy in developing therapeutics, providing potential benefits for the medical field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
conferences
-
News
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
Rhea-AI Summary

Eterna Therapeutics Inc. will present at the ASGCT 27th Annual Meeting on the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features, potentially improving the therapeutic potential of MSCs in treating inflammatory diseases. The presentation aims to address challenges such as variability in therapeutic responses and in vivo persistence of MSCs, offering promising solutions for autoimmune and inflammatory indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.5%
Tags
conferences
News
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
Rhea-AI Summary
Eterna Therapeutics Inc. (ERNA) appoints Peter Cicala, JD, to its Board of Directors, bringing deep biotechnology and pharmaceutical industry experience. Cicala's expertise in intellectual property and strategic management aims to drive value creation and advance next-generation therapies using mRNA cell engineering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
management
-
News
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
Rhea-AI Summary
Eterna Therapeutics Inc. (Nasdaq: ERNA) granted a non-qualified stock option to its new President and CEO, Sanjeev Luther, to purchase 1,685,218 shares of common stock at an exercise price of $1.80 per share. The stock option will vest over four years, subject to Mr. Luther's continued service to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
-
News
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
Rhea-AI Summary
Eterna Therapeutics Inc. (Nasdaq: ERNA) has appointed Sanjeev Luther as President and CEO, effective January 1, 2024. Luther brings over 30 years of experience in leadership roles across biotechnology and pharmaceutical companies and has a track record of strategic planning and business development. The company aims to capitalize on its in-licensed portfolio of patented mRNA cell engineering technologies under Luther's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
News
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
Rhea-AI Summary
Eterna Therapeutics Inc. (Nasdaq: ERNA) announced a private placement transaction to sell approximately $9.2 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase an aggregate of 9,579,014 shares of common stock. The notes will bear interest at a rate of 12.0% per year, payable quarterly, and mature five years after issuance unless earlier redeemed, repurchased, or converted. Each purchaser of the convertible notes will receive warrants to purchase 200% of the number of shares of Eterna common stock into which such purchaser’s note is initially convertible. The offer and sale of the securities have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.57%
Tags
none
-
News
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
Rhea-AI Summary
Eterna Therapeutics Inc. has appointed James Bristol, Ph.D., to its Board of Directors. Dr. Bristol is a seasoned biopharmaceutical executive with over 30 years of experience in research and development and drug discovery. He has held various leadership roles in the industry and has been actively involved in multiple Boards of Directors and advisory roles. Eterna is excited to have him join the company as they continue their mission of developing next-generation therapies using mRNA cell engineering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.77%
Tags
management
-
News
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
Rhea-AI Summary
Eterna Therapeutics initiates development of novel hypoimmune iPSC line under collaboration with Lineage Cell Therapeutics for cell transplant therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
partnership
News
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
Rhea-AI Summary
Eterna Therapeutics appoints Dorothy Clarke to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
management
Stock ERNA logo
Eterna Therapeutics Inc.

Nasdaq:ERNA

ERNA Rankings

#5385 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ERNA Stock Data

10.71M
2.95M
39.31%
16.19%
0.78%
Television Broadcasting
Information
Link
United States of America
CAMBRIDGE

About ERNA

brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.